Effect of atorvastatin in the treatment of nonalcoholic fatty liver disease
10.3760/cma.j.issn.1008-6706.2016.08.014
- VernacularTitle:阿托伐他汀对非酒精性脂肪肝的疗效评价
- Author:
Qian BAI
;
Qiang WANG
- Publication Type:Journal Article
- Keywords:
Fatty liver;
Atorvastatin;
Liver function tests;
Ultrasonography
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(8):1171-1174
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of atorvastatin in the treatment of nonalcoholic fatty liver disease and its clinical application value.Methods 110 patients with nonalcoholic fatty liver disease were randomly divided into observation group and control group,55 cases in each group.The control group was given compound dichloroace-tate diisopropylamine orally,the observation group was given atorvastatin therapy.The effects of the two groups were recorded.Results In the observation group after treatment,the alanine aminotransferase was (39.78 ±3.45) U/L, aspartate aminotransferase was (29.17 ±3.17) U/L,gamma glutamine transpeptidase was (54.28 ±4.11) U/L.In the control group after treatment,the alanine aminotransferase was (52.78 ±6.81) U/L,aspartate aminotransferase was (39.96 ±6.21)U/L,gamma glutamine transpeptidase was (68.69 ±8.31)U/L,there were statistically signifi-cant differences between the two groups(t=12.6290,11.4770,11.5273,all P<0.05).In the observation group after treatment,the triglycerides was (1.66 ±0.32)mmol/L,total cholesterol was (3.27 ±0.37)mmol/L,low density lipo-protein was (1.94 ±0.45)mmol/L.In the control group after treatment,the triglycerides was (2.38 ±0.92)mmol/L,total cholesterol was (5.74 ±1.49)mmol/L,low density lipoprotein was (3.46 ±1.17)mmol/L,there were statis-tically significant differences between the two groups(t=5.4818,11.9316,8.9925,all P<0.05).In the observation group after treatment,the ultrasonic score was (1.33 ±0.12),liver/spleen CT ratio was (0.33 ±0.08).In the con-trol group after treatment,the ultrasonic score was (1.78 ±0.35),liver/spleen CT ratio was (0.47 ±0.21),there were statistically significant differences between the two groups(t =9.0197,4.6202,all P <0.05).Conclusion Atorvastatin in the treatment of nonalcoholic fatty liver disease can effectively improve the liver function,reduce blood lipid concentration,minor adverse reactions,and it is worth popularizing in clinical use.
